Two members of the retinoblastoma pathway, TOP2A and CDK1, were further shown as potential diagnostic biomarkers to distinguish leiomyomas from leiomyosarcomas and as prognostic tools in leiomyosarcoma patients. The gene discussed is CDK1; the disease is leiomyoma.